|
ev3 Stage: Venture, Growth Date of Investment: 2000 Web Site : http://www.ev3.net Stock Symbol : NASDAQ: EVVV |
 |
Founded in 2000 by Warburg Pincus, ev3 is a specialty medical device company focused on identifying and developing novel technologies in underserved treatment markets for cardiovascular, neurovascular, and peripheral vascular diseases. ev3 's diverse yet synergistic portfolio of novel endovascular technologies offer the potential to pioneer meaningful new endovascular treatments and capture significant market share in emerging endovascular device segments. Headquartered in Plymouth, Minnesota and currently operational in North America, Europe and the major markets of Asia and Latin America, ev3 has leveraged its extensive sales and marketing infrastructure to serve as the exclusive international distributor for Micro Therapeutics and the exclusive U.S. distributor of Invatec s.r.l. ("Invatec"), a private Italian manufacturer of peripheral products. Since the company's founding, Warburg Pincus has fostered the company's product development strategy by funding internal development programs and five strategic product and company acquisitions. Warburg Pincus has also helped in the recruitment of a roster of highly talented managers with extensive experience in all aspects of the interventional devices business, including sales and marketing, clinical trials, regulatory approvals, and research and development. On June 16, 2005, ev3 completed its initial public offering, raising $120 million in net proceeds for the company. ev3 acquired Micro Therapeutics in January 2006.
